M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next week in a grim mood.

Among significant news in a holiday spattered week, Dutch biotech argenx gained another approval in Japan for its Vyvdura (efgartigimod alfa and hyaluronidase-qvf), this time for adult patients with ...

In a report released yesterday, Myles Minter from William Blair reiterated a Buy rating on Axsome Therapeutics (AXSM – Research Report). The ...

The company recently announced results from two Phase 3 trials of AXS-05 for agitation. ACCORD-2, hit its main goal, but ...

With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

Axsome Therapeutics Inc (AXSM) stock saw a decline, ending the day at $84.78 which represents a decrease of $-1.92 or -2.21% from the prior close of $86.7. The stock opened at $82 and touched a low of ...

Axsome Therapeutics shows strong revenue growth with promising pipeline drugs for migraine, fibromyalgia, and narcolepsy.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 ...

US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 ...

Needham & Company LLC reiterated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research ...

In a report released yesterday, Vikram Purohit from Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), ...

Axsome Therapeutics, Inc. has successfully completed its phase 3 clinical program for AXS-05 in treating Alzheimer’s disease agitation. The ACCORD-2 trial achieved the primary endpoint by ...